Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer from 18 to 65 years old~* Subject determined in good health by a doctor~* Signature of free and informed consent~* Affiliated to the French healthcare insurance~* Fluent in French~Exclusion Criteria:~* Active bacterial or viral infection~* Immunocompromised~* Body mass index \<20 or\> 30 kg / m2~* Kidney failure with glomerular filtration rate \<90ml / min / m2 calculated according to the CKD-EPI method~* Known or suspected liver disease~* Pregnant or lactating woman~* Guardianship or curators~* Any situation that could interfere with the self / hetero assessment of pain (dementia, psychiatric disorders, for example)~* Concomitant intake of myotoxic drugs (statins, fibrates, ciclosporin, for example)~* Allergy or known side effects to daptomycin~* Dermatological pathologies which may interfere with the subcutaneous injection (eczema, psoriasis, etc.)~* Localized tattoo or piercing on the abdomen which may interfere with the subcutaneous injection or the evaluation of possible local effects of the injection~* Parenteral exposure to daptomycin in the previous 30 days~* The inclusion of the subject in another interventional research protocol (during the present study and in the 3 months before inclusion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Dapto SC-IV (Type: OTHER): First stage :~* Subcutaneous injection of daptomycin 10mg/kg~* Subcutaneous injection of placebo (physiological serum)~Second stage :~- Intravenous injection of daptomycin 10mg/kg
- Dapto IV-SC (Type: OTHER): First stage :~- Intravenous injection of daptomycin 10mg/kg~Second stage :~* Subcutaneous injection of daptomycin 10mg/kg~* Subcutaneous injection of placebo (physiological serum)

Based on this trial design, predict the completion outcome and termination type (if applicable).